---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000020"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T20:04:24.088206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# USANA reports preliminary FY2022 net sales ~$995M, EPS ~$3.65; guides FY2023 net sales $850-950M, EPS $2.35-$3.30

## Summary
- Preliminary FY2022 net sales ~$995M, diluted EPS ~$3.65, above prior guidance of $955-975M and $3.15-$3.40.
- Active Customers ~490,000 at year-end; incremental sales in China from COVID policy shift, but uncertainty persists.
- Initial FY2023 guidance: net sales $850-950M, diluted EPS $2.35-$3.30, reflecting lower starting customer base and currency headwinds.
- Company to report final Q4/FY2022 results on Feb 7, 2023; conference call Feb 8.

## SEC filing metadata
- accession: 0001157523-23-000020
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/a53173940.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000020
- JSON: https://secwatch.observer/filing/0001157523-23-000020.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000020.txt

## Key facts
- Earnings Releases
  USANA HEALTH SCIENCES INC reported the full fiscal year ended December 31, 2022 results: revenue approximately $995 million, EPS approximately $3.65.
  - Period: the full fiscal year ended December 31, 2022
  - Revenue: approximately $995 million
  - EPS: approximately $3.65
  - Result: preliminary results
  source text: The Company currently anticipates fiscal year 2022 net sales of approximately $995 million and diluted earnings per share of approximately $3.65.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm
- Earnings Releases
  USANA HEALTH SCIENCES INC reported the fiscal year ending December 30, 2023 results: revenue $850 - $950 million, EPS $2.35 - $3.30. Guidance initiated.
  - Period: the fiscal year ending December 30, 2023
  - Revenue: $850 - $950 million
  - EPS: $2.35 - $3.30
  - Guidance: initiated
  - Result: guidance update
  source text: Initial Fiscal Year 2023 Guidance Consolidated Net Sales $850 - $950 million Diluted EPS $2.35 - $3.30
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323000020/0001157523-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.